BioTech
Readout Newsletter: BioNTech, Roche, Prometheus news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with yet another megaround in biotech, a preview of some hotly anticipated data, and the perils of declining revenue.
The need-to-know this morning
- Roche and its partner Chugai said Enspryng, their IL-6-targeted antibody treatment, “did not reach our expectations on the degree of clinical benefit” in a Phase 3 study of the autoimmune disorder myasthenia gravis.
- Shares of Argenx reacted positively to the Enspryng setback. Argenx’s FcRN-targeted antibody drug, Vyvgart, is approved to treat patients with myasthenia gravis. Shares of Immunovant, developing its own FcRN antibody, were also up. Tourmaline Bio, maker of an IL-6 antibody, saw its stock price fall.
After an $11 billion sale, the team behind Prometheus has a new startup
And it just raised $400 million to, like its predecessor, develop new medicines for inflammatory diseases.
Get unlimited access to award-winning journalism and exclusive events.
